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Almost three decades have passed since the historical NIH con-
sensus conference which paved the road for introduction of liver
transplantation (LT) into routine clinical practice worldwide. Pro-
gress in technical and medical skills as well as development of
potent anti-rejection agents led to a progressively improved
long-term survival of patients who underwent LT, 20 and even
30 years ago. In the early years of liver transplantation, guideline
driven protocol liver biopsies were used extensively to study the
natural history, response to anti-rejection treatment, recurrence
of the original liver disease and complications of LT. The cumula-
tive experience gained through these investigations led to a num-
ber of conclusions [1–7]: (1) Histo-pathologic abnormalities in
relatively old grafts followed up to 15 years, did not necessarily
correlate with disturbed standard liver function tests which
may remain intact. (2) Routine liver function tests have a low
speciﬁcity and sensitivity for diagnosis of rejection and remain
an inaccurate mean for assessment of graft dysfunction. (3) Pro-
tocol liver biopsies performed several years after LT, at a time of
normal liver function tests and in the absence of clinical signs,
may unmask signiﬁcant occult morbidities such as recurrence
of autoimmune liver disease, including PBC and PSC, hepatitis C
and advanced ﬁbrosis, chronic rejection (i.e. central venulitis, bile
duct loss and ﬁbrosis) or non-alcoholic fatty liver disease. (4)
Early recognition of histologic graft abnormalities may contribute
to better control and improve survival in patients with overt or
occult liver disease. (5) Unexplained idiopathic post-transplant
chronic hepatitis (IPTH), nodular regenerative hyperplasia and
hepatic structural changes including, hepatocyte disarray, perisi-
nusoidal ﬁbrosis, sinusoidal dilatation and peliosis hepatis have
been reported in up to 30% of protocol liver biopsies performed
P5 years after transplantation.
The practice of conducting protocol liver biopsies in LT patient
has changed in the past decade. A recent non-formal survey con-
ducted in 35 transplant centers reported by Mells et al. revealed
that only 25% of centers continue the practice of periodic protocol
liver graft biopsies at 1, 2, or 3, 5, 10 and 15 years post LT in non-
HCV patients [3]. Thus, despite proven beneﬁts documented by
periodic protocol planned liver biopsies, criticism against such
an approach has repeatedly been raised over the past 15 yearsJournal of Hepatology 20
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Open access under CC BY-NC-ND license.and still is the driving force for repeated assessment of progres-
sively growing databases [1–7]. The arguments used by oppo-
nents of this practice include among others that histologic
changes of variable severity identiﬁed through protocol liver
biopsies in 5–90% of adult patients do not necessarily correlate
with clinical manifestations or affect the management of
patients; the possibility of sampling errors and inter-observer
variability in interpretation; the risk, albeit low, of complications
(morbidity with major complications 0.20–3.7% and mortality of
0.03–0.20%, determined in non transplant patients); the availabil-
ity of new non-invasive techniques, which although non-vali-
dated yet, may enable reasonable assessment of degree of
inﬂammation and ﬁbrosis as well as reduction in cost. In contrast,
proponents of protocol liver biopsies argue that such practice
enables the early recognition of occult rejection or disease recur-
rence and consequently will lead to adjustment of immune-sup-
pressive therapy; the fact that normal or almost normal liver
histology may improve identiﬁcation of LT patients who devel-
oped tolerance, thus enabling reduction or even discontinuation
of immune suppression and it’s associated adverse effects.
In the present issue of the Journal, Dr. Sebagh and co-workers
have reviewed retrospectively a relatively large cohort of 91 LT
patients who underwent protocol liver biopsies at 10, 15 and
20 years after transplantation [8]. Fifty-six patients who were
biopsied at 10 and/or 15 years and who did not undergo a proto-
col biopsy at year 20, served as controls. Until now, data on the
natural history of graft histology was available mainly for periods
up to 10 years (and in a few cases 15 years) after LT. The main
contribution of the present study is additional new information
extending the long-term histologic follow-up in such patients
who underwent LT for a variety of indications. As expected, only
10% of patients had normal or almost normal graft histology.
Overall abnormal histologic ﬁndings rose from 65% and 80% at
5 and 10 years post LT, respectively, to 90% at 20 years. At
20 years post LT, evidence for progressive liver injury over time
was detected in about one third of patients who had more than
one pathological disorder (combined disorders) as compared to
only 7% and 17% at 5 and 10 years post LT, respectively. The rate
of structural changes was 20% at year 20 and contributed signif-
icantly to the overall rise in abnormal histologic ﬁndings over
time. The most common etiology for histologic disorders in the
study cohort was viral liver disease (HBV and HCV) with a sub-
stantial number of patients who acquired viral infection post
LT. The second most common etiology was chronic rejection.
Importantly, results obtained through protocol liver biopsies lead
in part to modiﬁcation of immunosuppression regimens in 35% of12 vol. 56 j 751–752
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patients. Theseﬁndingsprovide support for proponents of protocol
liver biopsies even at 20 years post LT since they have a potential
impact on patient’s management. Other observations from the
present study suggest that non-invasive techniques such as Fibro-
Test-Acti Test and transient elastography are still not reliable
enough to diagnose the precise stage of ﬁbrosis in the graft as com-
pared to the gold standard of a liver biopsy. Although this is a ret-
rospective study and selection of patients and controls has not
been prospectively randomized, the report contains a wealth of
information which should interest hepatologists, surgeons and
pathologists alike who take care of LT patients.
In summary, the study of Sebagh et al. suggests that ‘‘late’’
protocol liver biopsies are important for broadening our knowl-
edge on the natural history, progression, management and prog-
nosis of the graft in LT patients, even at 20 years after
transplantation. Furthermore, individual beneﬁt has been docu-
mented in about one third of patients who underwent a protocol
liver biopsy which contributed to their management. Finally, LT
patients who do not present with clinical or laboratory signs of
hepatic dysfunction may have smoldering occult disease and
therefore may beneﬁt from protocol biopsies even 2 decades after
transplantation. Yet, despite all justiﬁcations, it is not realistic to
expect that late protocol liver biopsies will be accepted over-
whelmingly by the individual patients (or physicians) without
clinical evidence for hepatic dysfunction. However, protocol liver
biopsies remain an important tool for management of LT patients
and most probably will continue in large and designated trans-
plant centers worldwide.752 Journal of Hepatology 201Conﬂict of interest
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